Akebia Therapeutics (AKBA) AGM 2026 summary

Opening remarks and agenda

• Meeting called to order in an all-virtual format, ensuring equal participation rights for all stockholders.

• Board members, executive leadership, and independent auditor introduced.

• Notice of meeting and proxy statement confirmed as duly delivered to all stockholders of record.

• Quorum established with approximately 71% of shares represented.

Shareholder proposals

• Election of three Class III directors to serve until the 2029 Annual Meeting.

• Approval to amend the certificate of incorporation to increase authorized capital and common stock.

• Advisory vote on executive compensation (say-on-pay) and on the frequency of future say-on-pay votes.

• Ratification of Ernst & Young LLP as independent registered public accounting firm for the current fiscal year.

Overview of voting outcomes

• All Class III director nominees elected.

• Amendment to increase authorized shares approved.

• Advisory vote on executive compensation passed.

• Annual frequency selected for future advisory votes on executive compensation.

• Ernst & Young ratified as independent auditor.

• Final vote results to be filed in Form 8-K within four business days.